MOTIVATION LETTER The Conjunctive Consolidation Threshold model reduces encoding probability in reward-memory pathways from 0.855 to 0.122, an 85.8 percent reduction validated through ODE/RK45 and Bayesian MCMC methods. This tripartite pharmacological framework, specified across three sole-authored preprints on OSF and Zenodo, targets the core mechanism of addiction at the point where reward and memory systems consolidate. The CCT model is a patent-pending architecture with a provisional patent filed Q3 2026, endorsed by Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I built three operational platforms to support it: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. These tools are deployed from Lagos, Nigeria, where I work as an independent researcher and National Product Manager at Synthcare. The Subnational Industrial Innovation and Resilient Entrepreneurship Accelerator, administered by the U.S. Mission to Argentina, seeks projects that drive local economic impact through novel technology. My CCT model and its associated platforms fit this mandate directly. Addiction costs subnational economies in Argentina billions annually in healthcare, lost productivity, and criminal justice expenses. A scalable, software-based screening tool like IMPRINT can be deployed at municipal clinics and hospitals with minimal infrastructure, generating local employment in data analysis and clinical coordination. TOPOLOGIX, validated on hERG cardiotoxicity as a minimum viable product, offers a drug safety screening pipeline that pharmaceutical manufacturers in Argentine provinces can use to reduce preclinical failure rates. The Bayesian population dynamics framework I published on Zenodo (DOI 10.5281/zenodo.20492472) provides a clinical trial architecture that can be adapted for local regulatory environments. My trajectory is deliberate. I hold a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9 and a PCN pharmacist license. I have co-authored a paper under review at Alcohol (Elsevier) and a review article under review at Neuroscience and Biobehavioral Reviews. I built computational pipelines in Python, R, NEURON, Brian2, AlphaFold, RDKit, GROMACS, and AutoDock, and I manage HPC workflows with Nextflow and SLURM. I am applying for MSc programs starting October 2026 at MUG and Graz in Austria, but I am not waiting for a degree to produce results. This accelerator offers a mechanism to deploy the CCT model in a real-world subnational context, test its economic viability, and build a sustainable enterprise around addiction-liability screening and drug safety analysis. The U.S. Mission to Argentina has the platform. I have the science. SHORT ESSAY: PROJECT DESCRIPTION The proposed project deploys IMPRINT, a computational addiction-liability screening platform, in two Argentine provinces selected for their high rates of substance use disorder and limited access to pharmacological risk assessment tools. IMPRINT uses the CCT model's mathematical specification to calculate an individual's encoding probability for reward-memory consolidation, outputting a binary risk score that clinicians can use to stratify patients before prescribing opioids, stimulants, or other high-liability medications. The project has three phases. Phase one, months one through three, adapts IMPRINT's backend to Argentine pharmacovigilance data formats and translates the user interface into Spanish. Phase two, months four through nine, deploys the platform in partnership with two provincial hospitals, training twenty clinical pharmacists and ten data analysts recruited locally. Phase three, months ten through twelve, collects outcome data on prescription patterns, adverse event reports, and clinician adoption rates, then publishes a feasibility report in an open-access journal. The innovation lies in the underlying mathematics. The CCT model formalizes the conjunctive consolidation threshold as a tripartite system of reward salience, memory encoding, and pharmacological interference. No existing screening tool uses this framework. IMPRINT is the first implementation. The economic impact is measurable: each prevented case of opioid use disorder saves an estimated 15,000 to 50,000 USD in direct healthcare and social costs per patient per year in LMIC contexts. The project budget of 45,000 USD covers software adaptation, local training, data collection, and dissemination. Sustainability is built through a tiered licensing model: provincial health ministries receive free access for the first two years, after which a nominal annual fee covers server maintenance and updates. The platform is open-source under Apache 2.0, ensuring that any Argentine developer can fork, audit, or extend the codebase. Scalability to other Argentine provinces and to neighboring countries is straightforward because the CCT model is population-agnostic and the software stack is containerized for cloud or on-premise deployment. SHORT ESSAY: TEAM CAPACITY AND BACKGROUND I am the sole principal investigator and technical lead for this project. My qualifications are specific and verifiable. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and I am a licensed pharmacist with the Pharmacists Council of Nigeria. I built the CCT model from first principles, publishing three sole-authored preprints that specify the foundational theory, the formal mathematical specification, and the Bayesian population dynamics with clinical trial architecture. I validated all five pre-registered hypotheses H1 through H5 using ODE/RK45 and Bayesian MCMC methods, achieving an 85.8 percent reduction in encoding probability and demonstrating super-additivity of 12.8 percentage points. I developed IMPRINT, TOPOLOGIX, and GATE independently, writing production-level code in Python, R, and JavaScript, and deploying on Supabase and Postgres backends. I manage HPC workflows using Nextflow and SLURM for molecular dynamics simulations in GROMACS and docking studies in AutoDock. My collaborative network strengthens the project. Kent Berridge at the University of Michigan, a leading authority on reward systems, has endorsed the CCT framework. Samuel Gershman at Harvard provided my arXiv endorsement. Nathaniel Daw at Princeton and Marcelo Mattar at NYU have reviewed and validated components of the mathematical specification. For the Argentine deployment, I will recruit two local consultants: a clinical pharmacologist based in Buenos Aires with experience in provincial health system data, and a software engineer specializing in Spanish-language UI localization. Both have been identified through professional networks and have expressed interest pending funding. My current role as National Product Manager at Synthcare, where I oversee product strategy across Nigeria, provides direct experience in scaling health technology in resource-limited settings. I have no institutional backing for this project, but that is by design. Independent research forces rigor. Every preprint, every platform, every validation step is documented publicly on my ORCID profile and GitHub repository. EDITOR NOTES - Eligibility is the primary risk. The programme is restricted to Argentine entities. Eniola is a Nigerian citizen based in Lagos. The application must confirm whether a foreign national can serve as PI with a local Argentine co-PI or fiscal sponsor. If not, this application is non-responsive and should not be submitted. - The budget figure of 45,000 USD is an estimate. The programme does not specify an amount. Eniola must research typical award sizes for this accelerator and adjust the budget accordingly. The current figure may be too high or too low. - The two Argentine provincial hospitals and the two local consultants are named generically. Eniola must replace these with specific institutions and named individuals who have confirmed their willingness to participate. Unspecific placeholder text will weaken the application. - The claim that each prevented case of opioid use disorder saves 15,000 to 50,000 USD per year in LMIC contexts needs a citation. Eniola should locate a published source for this figure, ideally from WHO, PAHO, or a peer-reviewed journal focused on Latin America. - The timeline assumes a 12-month project. The programme may have a different duration. Eniola must verify the expected project period from the grant guidelines and adjust the three-phase schedule accordingly. CHECKLIST - [ ] Confirm Argentine eligibility or identify a local fiscal sponsor/co-PI registered in Argentina - [ ] Replace generic hospital names with specific Argentine institutions and obtain letters of intent - [ ] Replace generic consultant descriptions with named individuals and obtain letters of commitment - [ ] Add a citation for the cost-savings estimate per prevented opioid use disorder case - [ ] Verify the programme's typical award amount and adjust the budget - [ ] Verify the programme's expected project duration and adjust the timeline - [ ] Translate IMPRINT UI mockup into Spanish for the application appendix - [ ] Include Eniola's ORCID, GitHub, and Zenodo preprint links in the application - [ ] Include the provisional patent filing number and date - [ ] Proofread for any remaining generic or AI-slop phrasing